Cardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Earn Q1 2024 Earnings of ($0.06) Per Share

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Stock analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Cardiol Therapeutics in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst V. Bernardino expects that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.09) EPS and FY2028 earnings at $0.43 EPS.

Cardiol Therapeutics Trading Up 4.5 %

Shares of NASDAQ:CRDL opened at $1.84 on Wednesday. Cardiol Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.17. The stock has a market cap of $125.64 million, a price-to-earnings ratio of -5.58 and a beta of 0.95. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $1.68 and a 200-day moving average price of $1.20.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cardiol Therapeutics stock. Laird Norton Trust Company LLC increased its stake in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 63.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,000 shares of the company’s stock after acquiring an additional 38,673 shares during the period. Laird Norton Trust Company LLC owned about 0.15% of Cardiol Therapeutics worth $90,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 12.49% of the company’s stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.